about
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaA physical mechanism for coupling bone resorption and formation in adult human bone.Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Molecular pathogenesis of multiple myeloma and its premalignant precursor.Wnt and Wnt inhibitors in bone metastasis.Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis.Bone marker gene expression in calvarial bones: different bone microenvironments.Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease.
P2860
Q24619589-ECA91CFA-36EB-4FCB-BAD1-CA11F19A99E1Q30485638-8A1E5F10-9878-45B8-9E83-E88D1372EAFBQ34155848-D658BD4B-9597-4577-9885-9FB42E0F3532Q34174284-C6F6D277-FEE2-43A0-9276-F10595F536A3Q34307388-3C437391-B4DB-4458-9122-8D3538501EAAQ36054631-3B45993F-5002-4F46-AF71-53404A966DB9Q36092102-AC84D825-CE65-4D47-95AC-194C5968BFB8Q36162703-616B59A4-5D4A-403E-AE78-794211AF0422Q36290238-0F52963C-24AA-4D04-8DD9-567550BC8419Q37056355-062F0A79-41E2-45EE-BA6A-10E9C5C1748AQ37089072-637BF179-509C-477F-A0D1-74217B0D8411Q37166798-BCA2B7FD-6CDD-4DBD-B7E8-058EE83F82C3Q37234048-99B69854-84D9-4595-A380-D46DC0D61AFCQ38775716-3D36744B-9B8F-43BE-B077-F91CCB2F9285Q38906451-C0C6A720-EB43-430D-90DE-26C482122D1AQ39483693-38529981-981D-4127-B28C-70DEC7A7DFA8Q43582458-1B4030B4-CD4E-4A81-B47B-460A4D51D68BQ44488860-771FF3CF-C51A-4351-BE8C-46335225B687
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathophysiology of myeloma bone disease.
@en
Pathophysiology of myeloma bone disease.
@nl
type
label
Pathophysiology of myeloma bone disease.
@en
Pathophysiology of myeloma bone disease.
@nl
prefLabel
Pathophysiology of myeloma bone disease.
@en
Pathophysiology of myeloma bone disease.
@nl
P1476
Pathophysiology of myeloma bone disease.
@en
P2093
Flavia R Esteve
G David Roodman
P304
P356
10.1016/J.BEHA.2007.08.003
P577
2007-12-01T00:00:00Z